MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep taking Tagrisso even after they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.